Spectral Medical (STU:SD4) Piotroski F-Score: 3 (As of Jul. 15, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SD4 Spectral Medical Inc STU:SD4
14 GF Score
Price €0.83
GF Value €0.56
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Spectral Medical Piotroski F-Score?

Spectral Medical STU:SD4 +1.23% 14 Piotroski F-Score is 3 as of Jul. 15, 2026, which is at its 10-year median of 3.00. GuruFocus rates STU:SD4 with a GF Score™ of 14/100 and a GF Value™ of €0.56 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 73.08% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Spectral Medical has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Spectral Medical's Piotroski F-Score or its related term are showing as below:

STU:SD4' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 3

During the past 13 years, the highest Piotroski F-Score of Spectral Medical was 5. The lowest was 1. And the median was 3.

Spectral Medical  (STU:SD4) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Spectral Medical Piotroski F-Score Related Terms


Spectral Medical Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Spectral Medical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spectral Medical Piotroski F-Score Chart

Spectral Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 1.00 3.00 3.00

Spectral Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 3.00 3.00

STU:SD4 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Spectral Medical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectral Medical Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Spectral Medical's Piotroski F-Score falls into.


STU:SD4
14GF Score
Spectral Medical Inc STU:SD4
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -1.226 + -18.671 + -1.756 + -1.852 = €-23.51 Mil.
Cash Flow from Operations was -1.724 + -1.641 + -1.676 + -1.504 = €-6.55 Mil.
Revenue was 0.516 + 0.416 + 0.236 + 0.562 = €1.73 Mil.
Gross Profit was 0.331 + 0.398 + -0.34 + 0.508 = €0.90 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2.617 + 3.486 + 5.004 + 3.776 + 2.886) / 5 = €3.5538 Mil.
Total Assets at the begining of this year (Mar25) was €2.62 Mil.
Long-Term Debt & Capital Lease Obligation was €3.41 Mil.
Total Current Assets was €2.42 Mil.
Total Current Liabilities was €41.29 Mil.
Net Income was -2.984 + -6.648 + 2.114 + -8.122 = €-15.64 Mil.

Revenue was 0.319 + 0.334 + 0.432 + 0.369 = €1.45 Mil.
Gross Profit was -0.014 + 0.47 + -0.949 + 0.38 = €-0.11 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(3.326 + 6.829 + 5.467 + 3.566 + 2.617) / 5 = €4.361 Mil.
Total Assets at the begining of last year (Mar24) was €3.33 Mil.
Long-Term Debt & Capital Lease Obligation was €0.22 Mil.
Total Current Assets was €2.10 Mil.
Total Current Liabilities was €24.18 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Spectral Medical's current Net Income (TTM) was -23.51. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Spectral Medical's current Cash Flow from Operations (TTM) was -6.55. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-23.505/2.617
=-8.98165839

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-15.64/3.326
=-4.70234516

Spectral Medical's return on assets of this year was -8.98165839. Spectral Medical's return on assets of last year was -4.70234516. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Spectral Medical's current Net Income (TTM) was -23.51. Spectral Medical's current Cash Flow from Operations (TTM) was -6.55. ==> -6.55 > -23.51 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=3.409/3.5538
=0.95925488

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.218/4.361
=0.04998853

Spectral Medical's gearing of this year was 0.95925488. Spectral Medical's gearing of last year was 0.04998853. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2.417/41.292
=0.05853434

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2.101/24.183
=0.08687921

Spectral Medical's current ratio of this year was 0.05853434. Spectral Medical's current ratio of last year was 0.08687921. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Spectral Medical's number of shares in issue this year was 293.233. Spectral Medical's number of shares in issue last year was 284.76. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.897/1.73
=0.51849711

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-0.113/1.454
=-0.07771664

Spectral Medical's gross margin of this year was 0.51849711. Spectral Medical's gross margin of last year was -0.07771664. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1.73/2.617
=0.66106229

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1.454/3.326
=0.43716176

Spectral Medical's asset turnover of this year was 0.66106229. Spectral Medical's asset turnover of last year was 0.43716176. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Spectral Medical has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Spectral Medical (STU:SD4) has a Piotroski F-Score of 3 as of Jul. 15, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Spectral Medical and its competitors. This is near median its historical median of 3.00. Over the past decade, Spectral Medical's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, Spectral Medical ranks #152 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 73.1%.
Is Spectral Medical's Piotroski F-Score too high?
Spectral Medical's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Spectral Medical's value of 3 is 40% below this industry median. Based on the distribution chart, Spectral Medical ranks #152 out of 208 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Spectral Medical has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #152 out of 208 companies for Piotroski F-Score. This places Spectral Medical in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Spectral Medical's value of 3 is 40% below this benchmark. Historically, Spectral Medical's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Spectral Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spectral Medical's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (STU:SD4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.56, compared to a current price of €0.83 — trading 47.3% above its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 40% below the Medical Diagnostics & Research industry median of 5.00. Spectral Medical's overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Spectral Medical (STU:SD4), the current Piotroski F-Score is 3 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spectral Medical (STU:SD4) Overvalued in 2026?

Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued. The current stock price of €0.83 is trading 47.3% above its estimated GF Value™ of €0.56. GuruFocus considers Spectral Medical to be Significantly Overvalued.

Key valuation signals for STU:SD4:

  • Piotroski F-Score: 3 (near median its 10-year median of 3.00)
  • GF Value™: €0.56 vs. price of €0.83 (47.3% above fair value)
  • GF Score™: 14/100 with 9 warning signs
  • Industry Position: 40% below the Medical Diagnostics & Research median (#152 of 208)

No single metric tells the full story. See the STU:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spectral Medical Business Description

Other Exchanges EDTXF:USAEDT:Canada
Address 135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
14GF Score

Get the complete analysis for STU:SD4

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.83
Price
€0.56
GF Value